10-Q quarterly report · filed Oct 29, 2026

West Pharmaceutical Services (WST) Q3 2026 10-Q Quarterly Report

Short answer

West Pharmaceutical Services (WST) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $875M (up 8.7% year over year) with net income of $214M.

Q3 2026 key financials · XBRL

Revenue
$875M
+8.7% YoY · +0.3% QoQ
Net income
$214M
+52.9% YoY · +39.0% QoQ
Operating margin
30.6%
Gross margin
39.7%
EPS (diluted)
$3.02
+57.3% YoY · +40.5% QoQ

Source: XBRL data from the West Pharmaceutical Services (WST) Q3 2026 10-Q on SEC EDGAR. USD.

West Pharmaceutical Services Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $874.5M, up 8.7% YoY from $804.6M
  • Consolidated gross margin 39.7% vs 36.6%; operating margin 30.6% vs 20.8%
  • Best segment Proprietary Products: sales $728.8M, up 12.6%; worst West Vantage: $145.7M, down 7.3%
  • Operating cash flow $403.4M vs $503.7M; share repurchases $685.3M
  • Cash $464.1M vs $791.3M; headwinds from cyber-incident downtime, inflation and contract expiration

Risk Factors

  • New cybersecurity risk triggered by May 2026 attack, involving data exfiltration and global system encryption
  • Operational disruption from attack, requiring systems taken offline globally before full recovery
  • Regulatory exposure from compromised personal information, including potential fines and reputational damage
  • Financial risk from cybersecurity costs exceeding insurance policy limits
  • Evolving AI-enabled attack techniques increasing unauthorized-access risk

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other West Pharmaceutical Services quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.